Navigation Links
Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy
Date:10/20/2014

LONDON, October 20, 2014 /PRNewswire/ --

Norgine B.V. today announced that the Phase II study of its novel, low volume bowel preparation, NER1006, presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology (ACG), Philadelphia, PA, has met its primary efficacy end point of stool weight and co-primary endpoint of cleansing success. The study demonstrated high quality bowel cleansing efficacy with NER1006 vs. MOVIPREP® in screening colonoscopy patients.[1]

(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a)

The Phase II open-label, randomised study (OPT, n=240) investigated the pharmacodynamics (stool weight), clinical efficacy and tolerability of dose and taste-optimised low-volume PEG-based formulations (NER1006), after split dosing, compared with MOVIPREP®.[1] Results demonstrate that NER1006 achieved high quality bowel cleansing in screening colonoscopy patients, comparable with MOVIPREP®. Cleansing success rates were 90-100%.[1] Stool output was consistently higher with NER1006, and safety and tolerability profiles between treatments were comparable.[1] In addition, most subjects in the NER1006 arms reached clear effluent.[1]

"Effective bowel cleansing is vital to delivering a successful colonoscopy procedure. This Phase II study confirms that NER1006, a low volume preparation, is preferential for some patients and improves tolerability. We are hoping that the Phase III programme will further show the efficacy and tolerability of NER1006," commented Donna McVey, Chief Development Officer, Norgine.

Norgine has now enrolled the first patient into the first study of its Phase III programme, NOCT, a US study. The Phase III programme consists of three clinical trials: NOCT is a multicentre, randomised, parallel-group clinical trial that is expected to enrol 540 patients across two arms, MORA and DAYB are European studies to further investigate the bowel cleansing efficacy, compliance, safety, patient acceptability and tolerability of NER1006.

--------------------------------------------

References 

1. Halphen M, et al. Pharmacodynamic and clinical evaluation of low-volume polyethylene glycol based bowel cleansing solutions (NER1006) using split dosing in healthy and screening colonoscopy subjects. ACG 2014 abstract #P330 

 

See full release on http://www.norgine.com

Charlotte Andrews: Tel - +44-(0)1895-453669

Peter Martin: Tel- +44-(0)1895-453744

 

Job code: GL/COR/1014/0024

October 2014


'/>"/>
SOURCE Norgine B.V
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results
2. Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients
3. Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
4. SALVAT Announces Positive Top-line Results from Two Phase III Studies of its Novel Otic Antibiotic/Steroid Combination Solution in the Treatment of AOMT with Tympanostomy Tubes
5. Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients
6. Glenmarks TRPA1 Antagonist GRC 17536 Shows Positive Data in a Proof of Concept Study
7. ROX Medical presents positive data for CONTROL-HTN resistant hypertension trial
8. Aratana Therapeutics Reports Positive Effectiveness Data from Pilot Field Study of Bupivacaine Extended-Release Injectable Suspension (AT-003)
9. Blueprint Medicines Presents Positive Data on BLU-554 for Hepatocellular Carcinoma
10. Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan
11. Fractyl Labs Announces Positive Clinical Data for First Procedural Therapy to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/9/2018)... ... ... Cannabidiol, or CBD, has grabbed national headlines in recent months with its ... National Day Calendar collaborated with cbdMD to create a holiday in support of alternative, ... CBD Day after weeks of tireless planning in an effort to bring the holiday ...
(Date:8/7/2018)... ... 07, 2018 , ... Commissioner Gottlieb’s FDA:, Analysis of First Year and a ... ET, http://www.fdanews.com/commissionergottliebsfda , Under Commissioner Scott Gottlieb, changes at the FDA ... may have gotten hurt. , And Gottlieb is just getting started. , Mark the ...
(Date:8/7/2018)... Mich. (PRWEB) , ... August 07, 2018 , ... ... addition of Joe Morehouse, DO, to its growing team of eye care providers. ... for astigmatism, and traditional intraocular lenses, as well as treating patients for routine ...
Breaking Medicine Technology:
(Date:8/15/2018)... ... August 15, 2018 , ... Many people might desire more ... achieve it. That’s where a great new option comes in: Injectable filler, which can ... Au, MD of Advanced Dermatology P.C. , An increasingly popular option for ...
(Date:8/14/2018)... ... August 14, 2018 , ... Kathy Mills ... at ChiroTouch Connect User Conference. The ChiroTouch Conference is a one-day learning event ... , ChiroTouch is ecstatic to have Kathy Mills Chang lead the conference. Kath ...
(Date:8/14/2018)... ... August 14, 2018 , ... Ross A. Clevens, MD, FACS is ... at Clevens Face and Body Specialists. Dr. Clevens is known for introducing innovative techniques ... and Merritt Island offices. Along with his associate, Amy Simon, MD, FACS, Dr. Clevens ...
(Date:8/11/2018)... ... August 11, 2018 , ... Financial Voyages LLC ... the Executive of the Year-Business category in The 15th Annual International Business Awards®. ... individuals and organizations worldwide – public and private, for-profit and non-profit, large and ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... as an Operating Partner and will have an exclusive relationship with the firm. ... the firm’s strategic planning, human capital sourcing, and deal origination, evaluation and diligence. ...
Breaking Medicine News(10 mins):